Valve Science Center, Minneapolis Heart Institute Foundation, MN (P.S., H.S., V.N.B., J.L.C., R.B., M.F., L.S., M.E.-S.).
Minneapolis Heart Institute at Abbott Northwestern Hospital, MN (P.S., V.N.B., J.L.C., R.B.).
Circ Cardiovasc Interv. 2023 Feb;16(2):e012486. doi: 10.1161/CIRCINTERVENTIONS.122.012486. Epub 2023 Feb 21.
Consensus-driven criteria have recently been proposed for prediction of mitral transcatheter edge-to-edge repair outcomes, yet validation for response to therapy is needed. We examined the relation between contemporary criteria and outcomes with mitral transcatheter edge-to-edge repair therapy.
Mitral transcatheter edge-to-edge repair patients were classified according to anatomic and clinical criteria (1) Heart Valve Collaboratory criteria for nonsuitability; (2) commercial indications (suitable); and (3) neither (ie, intermediate). Analyses for Mitral Valve Academic Research Consortium-defined outcomes of reduction in mitral regurgitation and survival were performed.
Among 386 patients (median age, 82 years; 48% women), the most common classification was intermediate (46%), with 138 patients (36%) and 70 patients (18%) in the suitable and nonsuitable categories, respectively. Nonsuitable classification was related to prior valve surgery, smaller mitral valve area, type IIIa morphology, larger coaptation depth, and shorter posterior leaflet. Nonsuitable classification was associated with less technical success (<0.001) and survival free of mortality, heart failure hospitalization, and mitral surgery (<0.001). Among the nonsuitable patients, technical failure or any 30-day major adverse cardiac event occurred in 25.7%. Nevertheless, in these patients, acceptable mitral regurgitation reduction without adverse events still occurred in 69%, and their 1-year survival with mild or no symptoms was 52%.
Contemporary classification criteria identify patients less suitable for mitral transcatheter edge-to-edge repair with respect to acute procedural success and survival, though patients most commonly fit an intermediate category. In experienced centers, sufficient mitral regurgitation reduction can be achieved safely in the selected patients even with challenging anatomy.
最近提出了共识驱动的标准来预测二尖瓣经导管缘对缘修复的结果,但需要验证对治疗的反应。我们研究了当代标准与二尖瓣经导管缘对缘修复治疗的结果之间的关系。
根据解剖学和临床标准(1)心脏瓣膜合作研究组不适合标准;(2)商业适应证(适合);和(3)既不适合也不适合(即中间),对二尖瓣经导管缘对缘修复患者进行分类。对二尖瓣学术研究联合会定义的减少二尖瓣反流和生存率的结果进行了分析。
在 386 名患者(中位年龄 82 岁,48%为女性)中,最常见的分类是中间(46%),适合和不适合的分别有 138 名(36%)和 70 名(18%)患者。不适合的分类与既往瓣膜手术、较小的二尖瓣面积、IIIa 型形态、较大的对合深度和较短的后叶有关。不适合的分类与较低的技术成功率(<0.001)和死亡率、心力衰竭住院和二尖瓣手术的生存无关(<0.001)。在不适合的患者中,技术失败或任何 30 天主要不良心脏事件的发生率为 25.7%。然而,在这些患者中,69%仍可获得可接受的二尖瓣反流减少而无不良事件,1 年生存率为 52%,症状轻微或无症状。
当代分类标准确定了在急性程序成功率和生存方面不太适合二尖瓣经导管缘对缘修复的患者,尽管患者最常见的是中间类别。在经验丰富的中心,即使解剖结构具有挑战性,仍可安全地为选定患者实现足够的二尖瓣反流减少。